1Weickert TW, Goldberg TE, Marenco S, et al. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology, 2003,28 (12):2217-2218.
2Brunnauer A, Geiger E, Laux G. Neuroleptics and cognition. Psychiatr Prax,2003 ,30 (Suppl 2): 106-109.
4Harvey PD, Napolitano JA, Mao L, et al. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry, 2003,18 (9): 820-829.
5Chen PS, Yang YK, Su SF,et al. Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci,2004,58(2) :168-172.
6Breier A. Cognitive deficit in schizophrenia and its neurochemical basis.Br J Psychiatry,1999, ( Suppl 37) :16-18.
7Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of elozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry,2002,159(6) :1018-1028.
8Jeon YW, Polich J. P300 asymmetry in schizophrenia: a metaanalysis. Psychiatry Res,2001,104(1) :61-74.
7McDermott LM,Bemire KP.A meta-analysis of depression sever-ity and cognitive function[J].Affect Disorder,2009,119(1-3):1-8.
8Korn H. Schizophrenia and eye movement-a new diagnostic and therapeutic concept[J]. Med Hypotheses,2004,62:29-34.
9Rybakowski JK, Borkowska A. Eye movement and neuropsyehologieal studies in first-degree relatives of schizophrenic patients[ J]. Schizophr Res, 2002,54:105-110.
10Thaker GK, Avila MT, Hong EL, et al. A model of smooth pursuit eye movement deficit associated with the schizophrenia phenotype[ J]. Psychophysiology, 2003,40: 277-284.
